

1 **BRIEF REPORT**

2

3 **Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2**
4 **in adults who had initially received 2 doses of inactivated vaccine**

5

6 Eunice Y. C. Shiu¹, Samuel M. S. Cheng¹, Mario Martín-Sánchez¹, Niki Y. M. Au¹, Karl C. K.
7 Chan¹, John K. C. Li¹, Lison W. C. Fung¹, Leo L. H. Luk¹, Sara Chaothai¹, Tsz Chun Kwan¹,
8 Dennis K. M. Ip¹, Gabriel M. Leung^{1,2}, Leo L. M. Poon^{1,3,4}, J. S. Malik Peiris^{†1,3,4}, Nancy H. L.
9 Leung^{†1,2}, Benjamin J. Cowling^{†1,2}

10

11 †Joint senior authors with equal contribution

12

13 **Affiliations:**

14 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
15 Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special
16 Administrative Region, China.

17 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park,
18 New Territories, Hong Kong Special Administrative Region, China.

19 3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The
20 University of Hong Kong; Hong Kong Special Administrative Region, China.

21 4. Centre for Immunology and Infection, Hong Kong Science and Technology Park, New
22 Territories, Hong Kong Special Administrative Region, China.

23

24 **Corresponding author:**

25 Benjamin Cowling, School of Public Health, LKS Faculty of Medicine, The University of Hong

26 Kong; Hong Kong Special Administrative Region, China. bcowling@hku.hk

27

28 Running head: Robust immunity after BNT162b2 booster

29 Word count (abstract): 83

30 Word count (main text): 1,767

31 Clinicaltrials.gov registration: NCT05057182

32

33 **ABSTRACT**

34 We administered BNT162b2 as a third dose to 314 adults ≥ 30 years of age who had previously
35 received 2 doses of inactivated vaccine. We collected blood samples before the third dose and
36 again after 1, 6 and 12 months, and found stable levels of antibody responses to the ancestral
37 strain and Omicron BA.2 at 6-12 months after receipt of the BNT162b2 third dose, with
38 increased antibody levels in individuals who also received a fourth vaccine dose or reported a
39 SARS-CoV-2 infection during follow-up.

40

41 INTRODUCTION

42 A number of different SARS-COV-2 vaccine platforms have been widely used since late 2020 to
43 mitigate the morbidity and mortality impact of COVID-19. Inactivated vaccines have been some
44 of the most widely used vaccines, providing effective protection against severe COVID-19 [1,2],
45 but stimulating weaker neutralizing antibody responses after vaccination compared to other
46 vaccine platforms [3,4]. We established a trial to investigate the strength and durability of
47 antibody responses to a heterologous third dose of BNT162b2 (BioNTech/Fosun Pharma/Pfizer)
48 in adults ≥ 30 years of age who initially received two doses of an inactivated vaccine. We
49 previously reported initial antibody responses to the third dose of BNT162b2 [5] and durability
50 for up to six months [6], and here we report further data up to 12 months after receipt of the third
51 dose and investigate the effect of Omicron infections and fourth doses on antibody levels.

52

53 METHODS

54 *Study Design*

55 We established a single-arm open label trial in adults who had previously received two doses of
56 inactivated vaccine. Participants were eligible if they were at least 30 years of age, and had
57 received their second inactivated vaccine dose ≥ 90 days prior to enrollment in this trial.

58 Participants were ineligible if they had a history of laboratory-confirmed SARS-CoV-2 infection
59 prior to enrolment, if they met a contraindication for receipt of BNT162b2, were receiving
60 immunomodulatory medications, or were females who were pregnant or intending to become
61 pregnant in the upcoming 3 months.

62

63 We collected serum samples at enrollment immediately before administration of BNT162b2, and
64 again on day 28, day 182 and day 365. At enrollment we collected information on demographics
65 and self-reported SARS-CoV-2 infection history, and reviewed COVID-19 vaccination records.
66 We updated this information at the day 182 and day 365 visits including information on any
67 infections that had occurred during follow-up or any additional vaccine doses that had been
68 received.

69 70 ***Ethical approval and trial registration***

71 All participants provided written informed consent to participate. The study was approved by the
72 Institutional Review Board of the University of Hong Kong. The study is registered at
73 ClinicalTrials.gov (NCT05057182).

74 75 ***Laboratory Methods***

76 Sera was extracted from the clotted blood within 48 hours and stored at -80°C until subsequent
77 serologic testing. We tested serum samples with a surrogate virus neutralization test [7] for
78 which the kits were obtained from GeneScript USA Inc. (Piscataway, New Jersey) and the assays
79 were performed in accordance with the manufacturer's recommendations. Inhibition levels $\geq 30\%$
80 were considered positive. We tested antibody responses to the ancestral strain, Omicron BA.2
81 and we also tested the day 182 and 365 samples to Omicron BA.5. A random subset of samples
82 were tested with a plaque reduction neutralization test (PRNT) with live ancestral virus and
83 Omicron BA.2 virus [8]. PRNT assays were performed in duplicate using 24-well tissue culture
84 plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland) in a biosafety level 3 facility
85 using Vero E6 TMPRSS₂ cells. Serial dilutions from 1:10 to 1:320 of each serum sample were

86 incubated with 30-40 plaque-forming units of virus for 1 hour at 37°C. Virus-serum mixtures
87 were subsequently added onto pre-formed Vero E6 cell monolayers and incubated for 1 hour at
88 37°C in a 5% CO₂ incubator. The cell monolayer was then overlaid with 1% agarose in cell
89 culture medium and incubated for 3 days, at which time the plates were fixed and stained [7,8].
90 PRNT₅₀ titers were defined as the highest serum dilution that resulted in ≥50% reduction in the
91 number of virus plaques. Positive and negative control sera were included in every experiment.
92 All assays listed above were previously validated and reported [9].

93

94 *Statistical Analysis*

95 We presented the sVNT inhibition (%) and PRNT₅₀ titers in serum samples collected at day 0,
96 day 28, day 182, day 365 after the administration of the third dose of BNT162b2. Information on
97 SARS-CoV-2 infections and the receipt of any additional booster doses during follow-up were
98 self-reported by participants. We compared the group means for surrogate virus neutralization
99 (sVNT) levels and the geometric mean PRNT₅₀ titers in the serum samples between groups using
100 t tests. Statistical analyses were conducted using R version 4.2.2 (R Foundation for Statistical
101 Computing, Vienna, Austria).

102

103 **RESULTS**

104 We enrolled and administered BNT162b2 as a third dose to 314 participants between 18 October
105 and 28 December 2021. We successfully followed up 277 (88%) through to the day 365 blood
106 draw, including day 28 samples from 312 (99%) participants and day 182 samples from 284
107 (90%) participants. The day 365 samples were collected from 26 September 2022 through to 13
108 February 2023. Participants who completed the day 365 blood collection had a median age at

109 enrolment of 54 years; IQR: 48 - 62) and 62% were male. The age and sex distribution of the
110 12% of enrolled participants who did not provide day 365 blood samples were similar to those
111 who did provide samples at day 365, with a median age at enrolment of 48 years (IQR: 40 - 61)
112 and 59% being male.

113
114 During the follow-up period, among the 277 participants followed through to day 365, 98
115 reported receipt of a fourth dose and these were received between April 2022 and December
116 2022. Among these fourth doses, the majority were with monovalent BNT162b2 (86, 88%), with
117 11 participants receiving the monovalent CoronaVac and one participant receiving the bivalent
118 formulation of BNT162b2. Two participants reported receiving a fifth dose of bivalent
119 BNT162b2 at 13 and 42 days prior to day 365. 76 participants reported a SARS-CoV-2 infection
120 confirmed by PCR or by rapid antigen test between February 2022 and November 2022, with the
121 majority of these (35, 46%) occurring during the month of March 2022. 20 participants reported
122 both a fourth dose and a confirmed SARS-CoV-2 infection, of which 11 received the fourth dose
123 prior to infection (median days, 33; range, 1-133), and the remaining 9 received a fourth dose
124 after the infection occurred (median days, 176; range, 22-222). One participant received a fourth
125 dose one month after the confirmed infection, and subsequently received a fifth dose 8 months
126 later.

127 Among individuals without a reported infection or a fourth dose of vaccination, antibody
128 responses against the ancestral and Omicron BA.2 strain were substantially higher in all assays
129 after the third dose, declined by 6 months, and were similar at 12 months with no apparent
130 further decline (Figure 1C and 1D). In comparison, PRNT₅₀ titers of the Omicron BA.2 strain
131 were higher at the subsequent blood draw among those who reported a SARS-CoV-2 infection,

132 with the geometric mean PRNT₅₀ titer of 128 at 6 months and 69 at 12 months (Figure 1D). In a
133 subset of participants who reported a SARS-CoV-2 infection in addition to the receipt of a fourth
134 dose prior to day 365, the antibody titers against BA.2 were higher at day 365 with the geometric
135 mean of PRNT₅₀ titer of 127 as compared to the geometric mean titers of 69 in adults with
136 infection only ($p<0.01$) and 25 with a fourth dose only ($p<0.01$) (Figure 1).

137 We further examined changes over time in antibody levels against the Omicron BA.2 and BA.5
138 subvariants in those who reported receipt of a fourth dose of monovalent BNT162b2 or reported
139 an infection. There was a decreasing trend in the PRNT₅₀ levels against BA.2 and the sVNT
140 levels against BA.2 and BA.5 in participants from one month up to six months after the receipt
141 of a fourth dose of monovalent BNT162b2 only, or from one month up to six months after
142 infection and without receipt of any additional booster doses (Figure 2). In the group who
143 received a fourth dose, the antibody levels against BA.2 were maintained at high levels after 2
144 months, but gradually waned to a median PRNT₅₀ titer of approximately 20 and a median sVNT
145 level of 55% at 6 months. The antibody levels after reported infection also waned over time, but
146 the median PRNT₅₀ titer remained above 40 and the median sVNT level remained above 60% at
147 8 months post-infection. There were insufficient participants and data points to examine changes
148 over time in antibody titers after a fourth vaccine dose with CoronaVac or bivalent BNT162b2,
149 or after a fifth vaccine dose.

150

151 **DISCUSSION**

152 The result of this study show that a third vaccine dose with monovalent BNT162b2 increased
153 antibody levels against the ancestral strain and Omicron BA.2 strain in adults who had received 2
154 doses of inactivated vaccines, and antibody levels remained above a predicted protective

155 threshold against infection [7] for at least 12 months after the third dose. Antibody levels
156 gradually declined over time since the third dose, but additional booster doses or infections were
157 associated with higher antibody levels at day 365 (Figure 1).

158
159 Among participants who received a fourth dose, 88% received monovalent BNT162b2. The
160 monovalent BNT162b2, containing mRNA of the ancestral strain, may provide some degree of
161 protection against the Omicron strains [10]. In our study, the antibody titer against the Omicron
162 BA.2 strain in participants with receipt of a fourth dose of monovalent BNT162b2 was higher
163 than the predicted protective threshold at 6 months and 12 months, but it was comparatively
164 lower than the titers in participants with reported infection, even with a longer delay from
165 infection to day 365 blood collection (median delay from infection, 210 days; median delay from
166 fourth dose, 156). Most infections in our cohort were reported during a large community
167 epidemic of the Omicron BA.2 subvariant in Hong Kong [11], likely explaining why the
168 antibody levels against Omicron BA.2 were much higher in infected individuals than the
169 individuals with a fourth dose of monovalent BNT162b2 (Figure 2).

170
171 A relatively small number of participants reported receipt of bivalent BNT162b2 prior to day
172 365, therefore we were unable to assess the antibody responses from bivalent BNT162b2 here.
173 Our study has several other limitations. We observed an infection rate of 24% in our cohort,
174 which was slightly less than the estimated 41% infection rate during the Omicron wave in Hong
175 Kong [12], although receipt of the third dose in our study between October and December 2021
176 might have provided some degree of protection against confirmed SARS-CoV-2 infection in
177 March 2022 [10,13]. Only one participant reported two episodes of COVID-19 infection during

178 the 1-year follow up period, but some unrecognized infections/re-infections might have occurred.

179 Finally, while we measured antibody levels, we did not directly correlate these levels with the
180 degree of protection against infection, and this would be an important area for further research.

181

182 In conclusion, our study demonstrates that a BNT162b2 booster dose provides durable antibody
183 response in individuals who initially received two doses of an inactivated SARS-CoV-2 vaccine,
184 with participants maintaining high levels of sVNT antibodies at 12 months after receipt of the
185 third dose.

186

187

188 **ACKNOWLEDGMENTS**

189 We gratefully acknowledge colleagues including Zacary Chai, Sara Chaotahi, Kelvin Kwan,
190 Yvonne Ng, Teresa So, and Eileen Yu for technical support in preparing and conducting this
191 study; Anson Ho for setting up the database; Julie Au and Lilly Wang for administrative support;
192 Hetti Cheung, Victoria Wong, and Bobo Yeung at the University of Hong Kong (HKU) Health
193 System; Cindy Man and other colleagues at the HKU community Vaccination Centres at
194 Gleneagles Hospital; and all the study participants for facilitating the study.

195

196 **FINANCIAL SUPPORT**

197 This project was supported by the Theme-Based Research Scheme T11-705/21-N of the
198 Research Grants Council of the Hong Kong Special Administrative Region, China (to B. J. C.).
199 B. J. C. is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03)
200 from the Research Grants Council of the Hong Kong Special Administrative Region, China.

201

202 **DISCLAIMER**

203 The funding bodies had no role in the design of the study, the collection, analysis, and
204 interpretation of data, or writing of the manuscript.

205

206 **POTENTIAL CONFLICTS OF INTEREST**

207 B. J. C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax,
208 Pfizer, Roche, and Sanofi Pasteur, and has received research funding from Fosun Pharma. All
209 other authors report no potential conflicts.

210

211 **REFERENCES**


- 212 1. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses
213 of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based
214 observational study. *Lancet Infect Dis.* **2022**; 22(10):1435–1443.
- 215 2. Victora PC, Castro PMC, Gurzenda S, Medeiros AC, França GVA, Barros PAJD.
216 Estimating the early impact of vaccination against COVID-19 on deaths among elderly
217 people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality.
218 *EClinicalMedicine.* **2021**; 38:101036.
- 219 3. Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses to
220 BNT162b2 and CoronaVac. *Vaccine.* **2022**; 40(32):4312–4317.
- 221 4. Muena NA, García-Salum T, Pardo-Roa C, et al. Induction of SARS-CoV-2 neutralizing
222 antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected
223 individuals. *EBioMedicine.* **2022**; 78:103972.
- 224 5. Leung NHL, Cheng SMS, Martín-Sánchez M, et al. Immunogenicity of a Third Dose of
225 BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the
226 Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. *Clin Infect Dis.*
227 **2023**; 76(3):e299–e307.
- 228 6. Cowling BJ, Cheng SMS, Martín-Sánchez M, et al. Slow Waning of Antibodies Following
229 BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated
230 Vaccine. *J Infect Dis.* **2023**; 227(2):251–255.
- 231 7. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
232 antibody responses after infection and estimates of the duration of protection.
233 *EClinicalMedicine.* **2021**; 41:101174.

- 234 8. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-
235 2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2
236 vaccination. *Nat Med.* **2022**; 28(3):486–489.
- 237 9. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory
238 syndrome coronavirus 2 (SARS-CoV-2), March 2020. *Euro Surveill* [Internet]. **2020**;
239 25(16). Available from: <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.16.2000421>
- 240 10. Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and
241 CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of
242 SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. *Lancet Infect Dis.*
243 **2023**; 23(4):421–434.
- 244 11. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2
245 Omicron BA.2 Variant, Hong Kong, January-March 2022. *Emerg Infect Dis.* **2022**;
246 28(9):1856–1858.
- 247 12. Lau JJ, Cheng SMS, Leung K, et al. Real-world COVID-19 vaccine effectiveness against
248 the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. *Nat Med.* **2023**;
249 29(2):348–357.
- 250 13. Leung NHL, Cheng SMS, Cohen CA, et al. Homologous and heterologous boosting with
251 CoronaVac and BNT162b2: a randomized trial (the Cobovax study). *Lancet Microbe.*
252 **2023**; .

253

254

255



256

257 **Figure 1. Antibody titers by sVNT and PRNT₅₀ against live SARS-CoV-2 at day 0, day 28,**

258 **day 182 and day 365 after receipt of a third dose of BNT162b2 in participants. Analyses at**

259 **day 182 and 365 are stratified by reported SARS-CoV-2 infection or additional booster dose.**

260 **Panel A: antibody levels against the ancestral strain by sVNT, with X indicating the median**

261 **level. Panel B: antibody titers against the ancestral strain by PRNT₅₀, with X indicating the**

262 **median level. Panel C: antibody levels against the Omicron BA.2 strain by sVNT, with X**


263 **indicating the median level. Panel D: antibody titers against the Omicron BA.2 strain by**

264 **PRNT₅₀, with X indicating the median level. In panels A and C the dotted line at a value of 30%**

265 **represents the manufacturer's reported threshold for seropositivity on this assay.**

266

267



268

269

270

Figure 2. Antibody levels by time since third dose measured by a plaque reduction neutralization test and a surrogate virus neutralization test against Omicron BA.2 and

271 **Omicron BA.5 in individuals who reported a SARS-CoV-2 infection or a fourth dose of**
272 **monovalent BNT162b2 during follow-up.** Panel A: PRNT₅₀ titers against Omicron BA.2 by
273 time since receipt of a fourth dose of monovalent BNT162b2. Panel B: PRNT₅₀ titers against
274 Omicron BA.2 by time since self-reported SARS-CoV-2 infection. Panel C: sVNT antibody
275 levels against Omicron BA.2 by time since receipt of a fourth dose of monovalent BNT162b2.
276 Panel D: sVNT antibody levels against Omicron BA.2 by time since self-reported SARS-CoV-2
277 infection. Panel E: sVNT antibody levels against Omicron BA.5 by time since receipt of a fourth
278 dose of monovalent BNT162b2. Panel F: sVNT antibody levels against Omicron BA.5 by time
279 since self-reported SARS-CoV-2 infection. In each panels the smooth curve represents the
280 smoothed average and the 95% pointwise confidence intervals are shown as dashed lines to
281 either side. In panel C, D, E and F the dotted horizontal lines at a value of 30% represent the
282 manufacturer's reported threshold for seropositivity on this assay.